To further understand the role of HER4 in trastuzumab-treated HER2 positive breast cancer cell lines, we performed HER4 knockdown by transient transfection with specific HER4 siRNAs, with or without trastuzumab treatment. Here, ERBB2 is linked to breast carcinoma.